Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Lai-Shan Tam, Chinese University of Hong Kong
ClinicalTrials.gov Identifier:
NCT00668330
First received: April 25, 2008
Last updated: February 10, 2012
Last verified: February 2012

April 25, 2008
February 10, 2012
April 2007
May 2009   (final data collection date for primary outcome measure)
The primary outcome of Part I study is to investigate the prevalence of low BMD and vertebral fractures. Primary outcome of part II study is the improvement of bone mineral density measured by DEXA. [ Time Frame: baseline and month 12 ] [ Designated as safety issue: Yes ]
The primary outcome of Part I study is to investigate the prevalence of low BMD and vertebral fractures. Primary outcome of part II study is the improvement of bone mineral density measured by DEXA. [ Time Frame: baseline and wk52 ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00668330 on ClinicalTrials.gov Archive Site
  • Evaluation of the changes in bone mineralization and architecture measured by Xtreme CT. [ Time Frame: baseline, month 6 and month 12 ] [ Designated as safety issue: Yes ]
    The study will be analyzed using intention-to-treat (ITT) analysis
  • Evaluation of the changes in perfusion and marrow edema using MRI. [ Time Frame: baseline, month 6, month 12 ] [ Designated as safety issue: Yes ]
    The study will be analyzed using intention-to-treat (ITT) analysis
1.Evaluation of the changes in bone mineralization and architecture measured by Xtreme CT. 2.Evaluation of the changes in perfusion and marrow edema using MRI. [ Time Frame: baseline, month 6 and month 12 ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus
Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus-Prevalence,Risk Factors and Treatment

The primary aim of the present study was to investigate the prevalence of low bone mineral density (BMD) and vertebral fractures, as determined by a standardized assessment, and to elucidate the role of bone qualities, including micro-architecture, bone remodeling, bone turnover, mineralization and inflammation on bone density and prevalent vertebral fractures in a large population of systemic lupus erythematosus (SLE) patients.

The secondary aim of the study is to evaluate the following parameters in women with steroid induced OP (SIOP) before and after 1 year of treatment using:

  1. The changes in BMD using dual energy X-ray absorptiometry (DXA)
  2. Bone mineralization and architecture in-vivo using a newly available high-resolution human micro-computed tomography (ExtremCT), which can provide us with new insights into how the degree and distribution of mineralization are affected by long-term oral Ibandronate treatment.
  3. Changes in perfusion and marrow edema before and after treatment of Ibandronate using dynamic Magnetic Resonance Imaging (MRI) in these patients with SIOP.
  4. The investigators prospectively evaluate the correlation between the changes in brachial arterial endothelial function and lumbar spine BMD in female lupus patients over the period of 1 year.

In the first part of the study, 150 consecutive patients with a diagnosis of SLE were included in the study. All patients fulfilled the American College of Rheumatology (ACR) revised criteria for the classification of SLE and provided written informed consent. Data collected at the time of study inclusion were age, disease duration, race, menstrual status, age at menopause, periods of amenorrhea, family history of osteoporosis, ultraviolet (UV) light intolerance, sunshine avoidance, use of sunscreens in the previous year, calculated mean daily dietary calcium intake in the last 3 months, history of (non)vertebral fractures after the age of 25 years, comorbidity, alcohol and tobacco intake, and exercise status.Body weight, height, and body mass index (BMI) were assessed. Disease activity was scored using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 54. Accumulated organ damage was assessed with the SLICC/ ACR damage index (DI) 55. A modified DI score was derived as the DI score excluding osteoporotic fractures as a damage item.BMD measurements of the hip (total hip and femoral neck) and the lumbar spine (L1-4; anteroposterior view) as well as lateral radiographs of the thoracic and lumbar spine (T5-L4)were performed. The prevalence of low BMD and vertebral fractures will be assessed.

In the second part of the study, 40 female SLE patients with steroid induced osteopenia will be enrolled in a 12-month, randomized, parallel-group, controlled study. Patients will receive either oral Ibandronate 150 mg once monthly plus daily alfacalcidol (0.001 mg) or placebo ibandronate once monthly plus daily alfacalcidol(0.001mg).In addition, the intake of dietary calcium will estimate by a questionnaire on the screening visit. All patients will receive a daily calcium supplement(500 mg).

Primary outcome is the improvement of bone mineral density measured by DEXA.

Secondary outcome includes:

  1. Evaluation of the changes in bone mineralization and architecture measured by Xtreme CT.
  2. Evaluation of the changes in perfusion and marrow edema using MRI.
  3. Anti-proliferative and anti-inflammatory action of alfacalcidol using serum level of interleukin-6 (IL-6), transforming growth factor-beta-1, angiotensin-II, as well as urinary levels of TGF and monocyte chemoattractant protein-1 (MCP-1).
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Systemic Lupus Erythematosus
  • Drug: Ibandronate+alfacalcidol+calcium
    Ibandronate 150 mg monthly plus daily alfacalcidol (1ug)500mg plus calcium
    Other Name: Bonviva
  • Drug: placebo ibandronate+alfacalcidol+calcium
    placebo ibandronate monthly plus daily alfacalcidol(1ug)500mg calcium
    Other Name: placebo Bonviva
  • Active Comparator: Ibandronate+alfacalcidol+calcium
    Bonviva
    Interventions:
    • Drug: Ibandronate+alfacalcidol+calcium
    • Drug: placebo ibandronate+alfacalcidol+calcium
  • Active Comparator: Placebo ibandronate+alfacalcidol+calcium
    Interventions:
    • Drug: Ibandronate+alfacalcidol+calcium
    • Drug: placebo ibandronate+alfacalcidol+calcium
Li EK, Zhu TY, Hung VY, Kwok AW, Lee VW, Lee KK, Griffith JF, Li M, Wong KC, Leung PC, Qin L, Tam LS. Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid. Arthritis Res Ther. 2010;12(5):R198. Epub 2010 Oct 22.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
May 2009
May 2009   (final data collection date for primary outcome measure)

Part I

Inclusion Criteria:

  • Fulfilled the ACR revised criteria for the classification of SLE
  • Provided written informed consent for their participation

Part II

Inclusion Criteria:

  • Have low BMD (T socre < -1 S.D. at the lumbar spine (L1-L4) or total hip) induced by the long-term administration of high-dose corticosteroids.
  • Had been receiving chronic uninterrupted corticosteroid therapy for at least 1 year or had received a corticosteroid dose of at least 5 mg/day.

Exclusion Criteria:

  • Hypocalcaemia, hypercalcaemia, Hypercalciuria, a creatinine clearance of less than 30 ml per minute.
  • A history of nephrolithiasis during the previous five years.
  • A history of recent major gastrointestinal (GI) tract disease (e.g. oesophagitis).
  • Had or presence of primary hyperparathyroidism, hyperthyroidism, or hypothyroidism in the year before the study began.
  • Had experienced any previous adverse reaction to bisphosphonate therapy (alendronate, fosamax, ibandronate).
  • With uncontrolled active or recurrent peptic ulcer disease.
  • Receiving therapy (within the last 6 months) known to affect bone metabolism, including:hormone-replacement agents, calcitonin, active vitamin D3 analogues, thiazide diuretics,treatment with bisphosphonates,fluoride treatment within the last 12 mons or for a total duration of 2 years; contraindications to calcium or vitamin D therapy.
  • Pregnant or breastfeeding.
Female
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
China
 
NCT00668330
SLE-2007-007
No
Lai-Shan Tam, Chinese University of Hong Kong
Chinese University of Hong Kong
Not Provided
Principal Investigator: Edmund K Li, MD Chinese University of Hong Kong
Chinese University of Hong Kong
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP